Health and social work services

Tender description

North of England Commissioning Support (NECS) is a commissioning support service hosted by NHS England and is managing this procurement process for and on behalf of Greater Manchester Health & Social Care Partnership (the Commissioner). This tender opportunity is for the provision of Diabetic Eye Screening Programme in Greater Manchester covering 2 Lots: Lot 1 Greater Manchester North Lot 2 Greater Manchester South Tenderers can bid on both Lots but the maximum number of lots that may be awarded to one tenderer is 1. Tender documents will be available on PROACTIS from 12:00 noon on 14.9.2017. The aim of the service is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment if necessary of sight threatening diabetic retinopathy, at the appropriate stage during the disease process. This will be achieved by delivering evidence-based, and population-based screening programmes that: — identify the eligible population and ensure effective delivery with maximum coverage; — are safe, effective, of a high quality, externally and independently monitored, and quality assured; — lead to earlier detection, appropriate referral, effective treatment and improved outcomes; — are delivered and supported by suitably trained, competent, and qualified, clinical and non-clinical staff who, where relevant, participate in recognised on-going Continuing Medical Education (CME), Continuous Professional Development (CPD), and Quality Assurance (QA) schemes; and — have audit embedded in the service The contract term will be for an initial period of 3 years with the option to extend the contract by a further 1 year at the discretion of the Commissioner and subject to satisfactory contractual and financial performance. The financial thresholds for this procurement is calculated at a maximum cost of 29.00 GBP per screen based upon indicative activity @ 80 % of the eligible population for each year. The aim of the service is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment if necessary of sight threatening diabetic retinopathy, at the appropriate stage during the disease process. This will be achieved by delivering evidence-based, and population-based screening programmes that: — identify the eligible population and ensure effective delivery with maximum coverage; — are safe, effective, of a high quality, externally and independently monitored, and quality assured; — lead to earlier detection, appropriate referral, effective treatment and improved outcomes; — are delivered and supported by suitably trained, competent, and qualified, clinical and non-clinical staff who, where relevant, participate in recognised on-going Continuing Medical Education (CME), Continuous Professional Development (CPD), and Quality Assurance (QA) schemes; and — have audit embedded in the service The contract term will be for an initial period of 3 years with the option to extend the contract by a further 1 year at the discretion of the Commissioner and subject to satisfactory contractual and financial performance. The financial thresholds for this procurement is calculated at a maximum cost of 29.00 GBP per screen based upon indicative activity @ 80 % of the eligible population for each year.